NPS Seeks Development Partners For Preos And Teduglutide, Reduces Force
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NPS Pharmaceuticals is reducing its workforce and consolidating operations while continuing to advance two pipeline candidates - the osteoporosis agent Preos and the gastrointestinal treatment teduglutide -following a review of its financial situation